PTC Therapeutics Withdraws Translarna NDA for Duchenne Muscular Dystrophy Following Negative FDA Feedback
Summary
PTC Therapeutics has withdrawn its New Drug Application resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy in the U.S. after receiving negative feedback from the FDA regarding the sufficiency of efficacy data.
Key Events
-
Translarna NDA Withdrawn
PTC Therapeutics announced the withdrawal of its New Drug Application (NDA) resubmission for Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (DMD) in the U.S.
-
FDA Feedback Cited
The withdrawal follows U.S. Food and Drug Administration (FDA) feedback indicating that the data in the NDA submission are unlikely to meet the Agency's threshold of substantial evidence of effectiveness to support approval.
-
Impact on U.S. Market
This decision effectively halts the path to U.S. market approval for Translarna for this indication, representing a significant blow to the company's pipeline and commercial prospects for the drug in the region.
Analysis
PTC Therapeutics' decision to withdraw its New Drug Application (NDA) resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy (DMD) in the U.S. is a significant setback. The FDA's feedback, indicating that the submitted data is unlikely to meet the threshold for substantial evidence of effectiveness, effectively closes the door on U.S. approval for this indication. This event negatively impacts the company's product pipeline and future revenue potential for Translarna in the critical U.S. market, raising questions about the long-term commercial strategy for the drug.
At the time of this filing, PTCT was trading at $69.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $35.95 to $87.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.